Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 18;7(2):355-64.
doi: 10.3980/j.issn.2222-3959.2014.02.30. eCollection 2014.

Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis

Xiao-Yu Zhang  1 , Xiao-Fan Guo  2 , Shao-Dan Zhang  1 , Jing-Na He  1 , Cao-Yu Sun  1 , Yin Zou  1 , Han-Si Bi  1 , Yang Qu  1
Affiliations

Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis

Xiao-Yu Zhang et al. Int J Ophthalmol. .

Abstract

Aim: To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.

Methods: We performed a comprehensive search of randomized controlled trials (RCTs), non-RCTs, case-control and cohort studies that compared bevacizumab and ranibizumab using PubMed and the Cochrane Library. After the related data were extracted by two investigators independently, pooled weighted mean differences (WMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects or a fixed-effects model.

Results: A total of four RCTs involving 1927 patients and eleven retrospective case series involving 2296 patients were included. For the primary outcomes, no significant differences were found between ranibizumab group and bevacizumab group in visual acuity (WMD: -0.04; 95%CI: -0.08 to 0.00; P=0.06), best corrected visual acuity (WMD: -0.05; 95%CI: -0.10 to 0.00; P=0.05), retina thickness (WMD: -4.69; 95%CI: -13.15 to 3.76; P=0.86) and foveal thickness (WMD: 10.91; 95%CI: -14.73 to 36.56; P=0.40). The pooled analyses in the evaluation of safety showed that compared to bevacizumab, ranibizumab was associated with decreased risks of ocular inflammation (RR: 0.45; 95% CI: 0.23 to 0.89; P=0.02) and venous thrombotic events (RR: 0.27; 95%CI: 0.08 to 0.89; P=0.03). However, there were no significant differences observed in deaths (P=0.69) and arterial thromboembolic events (P=0.71) between the two groups.

Conclusion: With equal clinical efficacy, ranibizumab was found to be associated with less adverse events compared to bevacizumab, indicating that ranibizumab might be a safer management.

Keywords: age-related macular degeneration; bevacizumab; ranibizumab.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow chart of literature search and study selection.
Figure 2
Figure 2. Forest plots for WMD of visual acuity after surgery comparing ranibizumab to bevacizumab.
Figure 3
Figure 3. Forest plots for WMD of central foveal thickness after surgery comparing ranibizumab to bevacizumab.
Figure 4
Figure 4. Forest plots for WMD of central retina thickness after surgery comparing ranibizumab to bevacizumab.
Figure 5
Figure 5. Forest plots: pooled results of head-to-head studies for different safety outcomes
A: Death (any cause); B: Arterial ihromboembolic events; C: Ocular inflammation; D: Venous thrombotic events.
See this image and copyright information in PMC

References

    1. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572. - PubMed
    1. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol. 1996;80(1):9–14. - PMC - PubMed
    1. VanNewkirk M, Weih LM, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the visual impairment project. Ophthalmology. 2001;108(5):960–967. - PubMed
    1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–851. - PMC - PubMed
    1. Chew EY, Lindblad AS, Clemons T. Summary results and recommendations from the age-related eye disease study. Arch Ophthalmol. 2009;127(12):1678–1679. - PMC - PubMed

LinkOut - more resources